UNSPSC 51343803: Efavirenz/emtricitabine/tenofovir

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

UNSPSC 51343803 Efavirenz/emtricitabine/tenofovir is a Commodity code that does not align with the recent state and local contract opportunities posted against it. The code nominally describes a specific antiretroviral pharmaceutical combination used in HIV treatment; however, the recent opportunities tagged to this code solicits naloxone and drug deactivation systems, therapeutic pharmacy initiative direct-to-manufacturer capabilities, general medical and first aid supplies for fire rescue operations, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. None of these opportunities directly procure efavirenz/emtricitabine/tenofovir or match the code's stated scope. The mismatch suggests either a tagging error in the source data or that state and local procurement offices are using this code as a catch-all pharmaceutical category rather than adhering to the specific commodity definition.

Recent activity appears across multiple issuing bodies and geographies: Seminole County, Florida posted an IFB for naloxone and drug deactivation systems with a response deadline of July 26, 2023; the City of Tampa issued an IFB for medical and first aid supplies (estimated contract value $700,000) with a response deadline of March 13, 2026, designated as a sheltered opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; the Texas Health and Human Services Commission issued an RFI on March 27, 2026, with a response deadline of April 3, 2026, exploring direct-to-manufacturer prescription capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance solicited generic pharmaceuticals and OTC products through an RFP due March 26, 2026, with participation from Oregon and other member jurisdictions. The issuing bodies span state health and human services agencies, county health departments, city fire departments, and multi-state cooperative purchasing organizations. Given the significant mismatch between the code's nominal scope and actual recent procurement activity, this code shows limited relevant activity for vendors focused on antiretroviral pharmaceutical products.